Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients

Epilepsy Research

Volumn 101, Issue 3, 2012, Pages 202-209

  Yamamoto, Yoshiaki ^a,b   Takahashi, Yukitoshi ^a   Suzuki, Eri ^b   Mishima, Nobuyuki ^a   Inoue, Kazuyuki ^b   Itoh, Kunihiko ^b   Kagawa, Yoshiyuki ^b   Inoue, Yushi ^a  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Epilepsy; Hepatic enzyme inducer; Hyperammonemia; Logistic regression analysis; Topiramate; Valproic acid

Indexed keywords

ACETAZOLAMIDE; AMMONIA; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DEPAKEN; DIAZEPAM; GABAPENTIN; LAMOTRIGINE; NEUROLEPTIC AGENT; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; SELENICA; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; AMMONIA BLOOD LEVEL; ANOREXIA; ARTICLE; ATAXIA; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EPILEPSY; FEMALE; HUMAN; HYPERAMMONEMIA; JAPANESE; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VOMITING;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; HYPERAMMONEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VALPROIC ACID;

EID: 84866160237     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.04.001     Document Type: Article

References (27)

1. Altunbaşak S., Baytok V., Tasouji M., Hergüner O., Burgut R., Kayrin L. Asymptomatic hyperammonemia in children treated with valproic acid. J. Child Neurol. 1997, 12:461-463.
2. Aires C.C., van Cruchten A., Ijlst L., de Almeida I.T., Duran M., Wanders R.J., Silva M.F. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J. Hepatol. 2011, 55:426-434.
3. Cagnon L., Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res. Rev. 2007, 56:183-197.
4. Carlson T., Reynolds C.A., Caplan R. Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:356-361.
5. Chicharro A.V., Kanner A.M. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?. Epilepsy Behav. 2007, 11:361-366.
6. Deutsch S.I., Burket J.A., Rosse R.B. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin. Neuropharmacol. 2009, 32:350-352.
7. Haidukewych D., John G., Zielinski J.J., Rodin E.A. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther. Drug Monit. 1985, 7:290-294.
8. Hamer H.M., Knake S., Schomburg U., Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000, 54:230-232.
9. Hamed S.A., Abdella M.M. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res. 2009, 86:32-41.
10. Hung T.Y., Chen C.C., Wang T.L., Su C.F., Wang R.F. Transient hyperammonemia in seizures: a prospective study. Epilepsia 2011, 52:2043-2049.
11. Ichikawa H., Amano T., Kawabata K., Kushiro M., Wada J., Nagake Y., Makino H. Fatal hyperammonemia in a patient with systemic lupus erythematosus. Intern. Med. 1998, 37:700-703.
12. Kim J.M., Ryu W.S., Hwang Y.H., Kim J.S. Aggravation of ataxia due to acetazolamide induced hyperammonaemia in episodic ataxia. J. Neurol. Neurosurg. Psychiatry 2007, 78:771-772.
13. Knudsen J.F., Sokol G.H., Flowers C.M. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J. Clin. Pharm. Ther. 2008, 33:513-519.
14. Kondo T., Ishida M., Kaneko S., Hirano T., Otani K., Fukushima Y., Muranaka H., Koide N., Yokoyama M., Nakata S. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?. Epilepsia 1992, 33:550-554.
15. Kugoh T., Yamamoto M., Hosokawa K. Blood ammonia level during valproic acid therapy. Jpn. J. Psychiatry Neurol. 1986, 40:663-668.
16. Laub M.C. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986, 27:55-59.
17. Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia. J. Inherit. Metab. Dis. 2008, 31:492-502.
18. Longin E., Teich M., Koelfen W., König S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 2002, 43:451-454.
19. Patsalos P.N., Fröscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 2002, 43:365-385.
20. Patsalos P.N., Berry D.J., Bourgeois B.F., Cloyd J.C., Glauser T.A., Johannessen S.I., Leppik I.E., Tomson T., Perucca E. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
21. Raskind J.Y., El-Chaar G.M. The role of carnitine supplementation during valproic acid therapy. Ann. Pharmacother. 2000, 34:630-638.
22. Ratnaike R.N., Schapel G.J., Purdie G., Rischbieth R.H., Hoffmann S. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br. J. Clin. Pharmacol. 1986, 22:100-103.
23. Verbiest H.B., Straver J.S., Colombo J.P., van der Vijver J.C., van Woerkom T.C. Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. Acta Neurol. Scand. 1992, 86:275-279.
24. Verrotti A., Greco R., Morgese G., Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int. J. Clin. Lab. Res. 1999, 29:36-40.
25. Warter J.M., Marescaux C., Chabrier G., Rumbach L., Micheletti G., Reitzer B., Hirsch E., Imler M. Increase of valproate-induced hyperammonemia in normal subjects by carbohydrate intake. Neurology 1984, 34:1487-1489.
26. Williams C.A., Tiefenbach S., McReynolds J.W. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 1984, 34:550-553.
27. Yagi M., Nakamura T., Okizuka Y., Oyazato Y., Kawasaki Y., Tsuneishi S., Sakaeda T., Matsuo M., Okumura K., Okamura N. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr. Int. 2010, 52:744-748.